Identifying Potential Drug Targets and Biomarkers of RPL7P44 (G390413)

Target Name: RPL7P44

NCBI ID: G390413

RPL7P44

Other Name(s): RPL7_17_1325 | Ribosomal protein L7 pseudogene 44 | ribosomal protein L7 pseudogene 44

Identifying Potential Drug Targets and Biomarkers of RPL7P44

RPL7P44 is a gene that encodes a protein known as RPL7, which is a key regulator of the poly(ADP-ribose) polymerase (PARP) complex. The PARP complex is a protein-protein interaction network that plays a crucial role in DNA repair and gene regulation. Mutations in the RPL7 gene have been associated with a variety of genetic disorders, including cancer, neurodegenerative diseases, and reproductive disorders.

The search for potential drug targets and biomarkers is an important aspect of modern medicine. Drug development involves identifying small molecules or other compounds that can interact with specific proteins and either inhibit or activate their activity. The identification of potential drug targets and biomarkers is an important step in this process, as it allows researchers to develop new treatments for a variety of diseases.

In this article, we will explore the potential drug target and biomarker of RPL7P44, focusing on its function in the PARP complex and its potential as a therapeutic target.

Functional Characterization of RPL7

The RPL7 gene encodes a protein that is composed of 1,942 amino acids. The protein has a molecular weight of 21 kDa and a pre-cleavage structure of 21 kDa. RPL7 is composed of two distinct regions: an N-terminal region that contains a nucleotide -binding oligomerization domain (NBO), and a C-terminal region that contains a catalytic domain.

The NBO region of RPL7 is a protein-protein interaction domain that is composed of a nucleotide-binding oligomerization domain (NBO) and a nucleotide-binding oligomerization domain (NBO). The NBO region plays a crucial role in the regulation of DNA repair and gene expression.

The C-terminal region of RPL7 contains a catalytic domain that is composed of a Rossmann-fold and a parallel beta-sheet. The Rossmann-fold is a structural domain that is composed of a beta-sheet and a Rossmann-region, while the beta-sheet is a structural domain that is composed of a beta-sheet and a alpha-helices. The catalytic domain of RPL7 contains a Rossmann-loop, a hydrogen bond network, and a structural domain that is composed of a beta-sheet and a alpha-helices.

The Role of RPL7 in the PARP Complex

The PARP complex is a protein-protein interaction network that plays a crucial role in DNA repair and gene regulation. The PARP complex is composed of several subunits, including the protein PARP1, PARP2, PARP3, and PARP4, as well as several non-protein subunits.

RPL7 is a key subunit of the PARP complex that is involved in the regulation of DNA repair and gene expression. RPL7 is a protein that can interact with the PARP1 protein and the PARP2 protein. These interactions are critical for the regulation of DNA repair and gene expression.

The NBO region of RPL7 is involved in the regulation of DNA repair. The NBO region can interact with the PARP1 protein and the PARP2 protein and can influence the activity of these proteins. These interactions can either enhance or inhibit the activity of the PARP1 and PARP2 proteins, depending on the specific context.

The catalytic domain of RPL7 is involved in the regulation of gene expression. The catalytic domain of RPL7 can interact with the PARP1 protein and the PARP2 protein and can influence the activity of these proteins. These interactions can either enhance or inhibit the activity of the PARP1 and PARP2 proteins, depending on the specific context.

Potential Drug Targets and Biomarkers

The identification of potential drug targets and biomarkers is an important aspect of modern medicine. The potential drug targets of RPL7P44, as a drug target for PARP inhibitors, are

Protein Name: Ribosomal Protein L7 Pseudogene 44

The "RPL7P44 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL7P44 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets